Pre-meeting Survey

2. Which first-line treatment regimens are preferentially considered in your hospital/institution for HR-positive/HER2-negative metastatic breast cancer patients not at risk of visceral crisis?*
(Please list the top 3 options in order of preference and state the reasons for considering each regimen selected)
5. Which guideline(s) do you follow when deciding on management for HR-positive/HER2-negative metastatic breast cancer patients?*
(Select all that apply)